Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 4/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 4/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770881 | 0.85 | TPSAB1 (0.48) | HSD11B1LMNACHRM1PRMT5WDR77 | |
| SCHEMBL770719 | 0.84 | EPHX2 (0.46) | HSD11B1LMNACHRM1PRMT5WDR77 | |
| SCHEMBL771875 | 0.81 | ATM (0.44) | HSD11B1LMNACHRM1TDP1EPHX2 | |
| SCHEMBL770761 | 0.81 | ATM (0.44) | HSD11B1LMNACHRM1TDP1EPHX2 | |
| SCHEMBL770576 | 0.81 | EPHX2 (0.49) | HSD11B1LMNACHRM1TPSAB1TPSD1 | |
| SCHEMBL772269 | 0.81 | ATM (0.44) | HSD11B1LMNACHRM1TDP1EPHX2 | |
| SCHEMBL770901 | 0.81 | LMNA (0.44) | HSD11B1LMNACHRM1TDP1EPHX2 | |
| SCHEMBL770918 | 0.81 | ITGB3 (0.45) | HSD11B1LMNACHRM1EPHX2 | |
| SCHEMBL770442 | 0.81 | HSD11B1 (0.42) | HSD11B1LMNACHRM1EPHX2 | |
| SCHEMBL770936 | 0.80 | EPHX1 (0.51) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885LMNA 3155/4885CHRM1 3030/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885LMNA 3116/4885CHRM1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.